Immucell Quick Ratio (ICCC) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Immucell Corporation  (NASDAQ: ICCC)

Immucell's Quick Ratio

ICCC's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the second quarter 2026, Quick Ratio fell to 1.51 below Immucell Corporation average.

Within In Vitro & In Vivo Diagnostic Substances industry 7 other companies have achieved higher Quick Ratio than Immucell in second quarter 2026. While Quick Ratio total ranking has improved so far during the Q2 2026 to 1532, from total ranking in the first quarter 2026 at 2781.

Explain Quick Ratio?
How much Cash & cash equivalents ICCC´s has?
What are ICCC´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ICCC Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 31.87 % 1.22 % -13.44 % -10.48 % -2.43 %
Y / Y Cash & cash equivalent Change - - - - -
Quick Ratio MRQ 1.51 1.74 0.74 0.97 -
ICCC's Total Ranking # 1532 # 2781 # 2312 # #
Seq. Current Liabilities Change 49.84 % -23.96 % 28.73 % -10.09 % 15.02 %
Seq. Cash & cash equivalent Change 30.06 % 78.96 % -2.04 % - -



Quick Ratio second quarter 2026 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 8
Healthcare Sector # 563
Overall Market # 1636


Quick Ratio Statistics
High Average Low
19.26 4.93 0
(Dec 31 2016)   (Mar 31 2022)




Financial Statements
Immucell's Current Liabilities $ 6 Millions Visit ICCC's Balance sheet
Immucell's Cash & cash equivalent $ 9 Millions Visit ICCC's Balance sheet
Source of ICCC's Sales Visit ICCC's Sales by Geography


Cumulative Immucell's Quick Ratio

ICCC's Quick Ratio for the trailling 12 Months

ICCC Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 1.05 % -7.06 % -8.85 % 5.75 % 16.11 %
Y / Y Cash & cash equivalent TTM Growth - 995.36 % 236.73 % 19.09 % -
Quick Ratio TTM 1.23 0.83 0.44 0.21 -
Total Ranking TTM # 1408 # 2381 # 2407 #
Seq. Current Liabilities TTM Growth 8.1 % 0.27 % -4.38 % -2.5 % -0.59 %
Seq. Cash & cash equivalent TTM Growth 61.08 % 88.56 % 97.96 % - -

Quick ratio ranking by company, industry and sector >> Back to ICCC Financial Strength Comparisons >> Go to Compare ICCC Quick Ratio to its Competitors

On the trailing twelve months basis ICCC Cash & cash equivalent grew by 30.06 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Immucell's Quick Ratio to 1.23, Quick Ratio remained below ICCC average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within In Vitro & In Vivo Diagnostic Substances industry 14 other companies have achieved higher Quick Ratio than Immucell. While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 3993.

Explain Quick Ratio?
How much Cash & cash equivalents ICCC´s has?
What are ICCC´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the In Vitro & In Vivo Diagnostic Substances Industry # 15
Healthcare Sector # 886
Within the Market # 1532


trailing twelve months Quick Ratio Statistics
High Average Low
4.99 2.41 0.08
  (Mar 31 2025)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within In Vitro & In Vivo Diagnostic Substances Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Qc Technologies Inc   3.00 $ 10.987  Millions$ 3.669  Millions
Alpha Teknova Inc   2.54 $ 17.436  Millions$ 6.872  Millions
Lantheus Holdings Inc   1.77 $ 593.298  Millions$ 335.677  Millions
Insight Molecular Diagnostics Inc   1.73 $ 17.756  Millions$ 10.286  Millions
Achieve Life Sciences Inc   1.65 $ 326.645  Millions$ 197.657  Millions
Immucell Corporation  1.51 $ 8.860  Millions$ 5.863  Millions
Myriad Genetics Inc   0.88 $ 115.200  Millions$ 130.700  Millions
Biomerica Inc   0.53 $ 1.308  Millions$ 2.481  Millions

Date modified: 2026-09-26T06:50:52+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.